Natco Pharma Limited has announced its registration approval given by CIB&RC recorded in it's Minutes of the 425
th Meeting held on 25.01.2021, for indigenous manufacture of Chlorantraniliprole (CTPR) Technical 93.00% w/ w min. under Section 9(3) of Insecticides Act, 1968. NATCO would be the 1
st indigenous manufacturer of this technical product.
CTPR technical is formulated into broad-spectrum insecticides used in several crops for better pest management. NATCO hopes to bri ng products based on CTPR shortly that would be affordable and accessible to farmers across India.
CTPR is an act ive ingredient used in products commercialized by FMC under brands Coragen® & Ferterra
®. The sales generated from CTPR containing products in India, inclusive of third-party marketing companies, as per declaration given by FMC was estimated to be INR 1540 crores in 2016. NATCO believes the current market size to be over Rs2000cr. NATCO has a pending litigation against FMC for declaration of freed om to use of CTPR.
Natco Pharma Ltd ended at Rs914.85 apiece up by Rs15.1 or 1.68% from its previous closing of Rs899.75 on the BSE.